HAE Stock Analysis: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$65.88
-0.49 (-0.74%)
▼
5d:
-1.91%
30d:
+19.09%
90d:
+1.87%
BUY
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: HAE shows positive signals but monitor for confirmation. Market pricing in 0.1% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: HAE shows positive signals but monitor for confirmation. Market pricing in 0.1% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$86.42
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$53.66
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $65.88, which is considered extended relative to its 30-day fair value range of $54.95 to $64.89. The stock's valuation (Forward PE: 12.5) is in line with its historical norms (12.5). At these levels, the market is pricing in 0.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HAE is in a downtrend. Immediate support is located at $55.75, while resistance sits at $68.33.
Market Sentiment: HAE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $81.60 (+22.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, HAE is in a downtrend. Immediate support is located at $55.75, while resistance sits at $68.33.
Market Sentiment: HAE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $81.60 (+22.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$54.95 -
$64.89
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.9% below Wall St target ($81.60)
- NEUTRAL: Market pricing in 0.1% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$54.95 -
$64.89
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$55.75
Resistance Level
$68.34
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.54
Wall Street Target
$81.60
(+22.9%)
Revenue Growth (YoY)
4.8%
Earnings Growth (YoY)
28.4%
Profit Margin
7.3%
Valuation Premium vs History
+0.1% premium
PE vs Historical
12.5 vs 12.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.1%
(market-implied from PE analysis)
1-Year Target
$66.44
(+0%)
2-Year Target
$66.50
(+0%)
3-Year Target
$66.57
(+0%)
3-Yr Target (if PE normalizes)
(PE: 13→13)
PE COMPRESSION
$66.34
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 7.0%)
$142.19
(+114%)
Base:
(SPY PE: 12.5, Growth: 7.0%)
$81.40
(+23%)
Bear:
(PE: 10.7, Growth: 7.0%)
$69.19
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 32.76 | Current EPS (TTM): $2.05
Bull Case
$147.75
(+120%)
Analyst growth 100.0%, PE expands to 36.0
Base Case
$134.32
(+100%)
Market implied 100.0%, PE stable at 32.8
Bear Case
$45.67
(-32%)
Severe decline -20.0%, PE contracts to 27.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 03, 2026 4:38 PM ET
Data refreshes hourly during market hours. Next update: 5:38 PM
Data refreshes hourly during market hours. Next update: 5:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$83 | 54 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$82 | 64 BUY |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$119 | 64 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$389 | 49 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$247 | 62 BUY |
